Abstract: Entinostat (MS-275) is a selective class I and IV histone deacetylase (HDAC) inhibitor that has emerged as a potent epigenetic therapeutic agent. While HDAC inhibitors have established roles in the treatment of hematological malignancies, entinostat has demonstrated significant potential in reversing therapeutic resistance—a concept known as episensitization—across various cancer types, including leukemia, breast cancer, and non-small cell lung cancer (NSCLC). This review synthesizes current literature on the pharmacological activity, molecular mechanisms, and structure-activity relationships of entinostat. Furthermore, it highlights current clinical limitations, such as off-target toxicities and fluid-electrolyte imbalances, and outlines future perspectives focusing on combination therapies with immune checkpoint inhibitors and other epigenetic modulators.
1. Introduction
Epigenetic modifications, including histone acetylation and DNA methylation, play a pivotal role in the regulation of gene expression and the maintenance of cellular homeostasis [2]. Aberrant epigenetic changes, such as histone hypoacetylation driven by the overexpression of histone deacetylases (HDACs), are frequently implicated in the silencing of tumor suppressor genes and the progression of various cancers [4]. To counteract these malignant transformations, HDAC inhibitors have been developed and successfully integrated into clinical oncology, particularly for hematological malignancies. For instance, agents like vorinostat, romidepsin, and belinostat are approved for T-cell lymphomas, while panobinostat is utilized in multiple myeloma [1][2].
Among these epigenetic modulators is Entinostat (MS-275), an oral synthetic benzamide derivative characterized by a long half-life and selective inhibition of class I and IV HDACs [1]. Notably, literature indicates that entinostat, alongside vorinostat, has been recognized for its application in the treatment of leukemia [5]. This review explores the therapeutic landscape of entinostat, emphasizing its role in hematological malignancies and its broader capacity to overcome drug resistance through epigenetic reprogramming.
2. Pharmacological Activity
Entinostat exhibits pleiotropic pharmacological activities, primarily functioning as an "episensitizer." Episensitization refers to the reprogramming of the tumor epigenome to restore sensitivity to previously failed therapies, challenging the traditional oncology doctrine that reusing failed therapies is ineffective [5][7]. In hematological contexts, entinostat has been noted for its efficacy and approval status in leukemia [5].
Beyond blood cancers, its pharmacological reach extends significantly to solid tumors. In hormone receptor-positive advanced breast cancer, entinostat combined with the aromatase inhibitor exemestane significantly improved progression-free and overall survival (as demonstrated in the ENCORE 301 trial) by modulating HER2 and estrogen receptor expression [1][4]. In non-small cell lung cancer (NSCLC), entinostat has been investigated in combination with the DNA methyltransferase inhibitor azacitidine, yielding durable responses in heavily pretreated patients by reversing the hypermethylation of key tumor suppressor genes [2][4]. Furthermore, entinostat enhances the efficacy of targeted therapies, such as erlotinib, particularly in patients exhibiting high E-cadherin levels [2].
3. Molecular Mechanism of Action
The primary mechanism of entinostat involves the selective binding and inhibition of class I and IV HDAC enzymes [1]. This inhibition leads to histone hyperacetylation, which relaxes the chromatin structure and facilitates the transcriptional activation of specific genes, including tumor suppressors and pro-apoptotic factors [1]. In addition to histone modifications, entinostat induces the acetylation of non-histone proteins. A critical target is the p53 tumor suppressor protein, which is activated directly through deacetylation and indirectly via reactive oxygen species (ROS)-induced DNA damage [4][5].
Entinostat also exerts profound effects on the tumor microenvironment and systemic immunity. It suppresses immunosuppressive cell populations, notably reducing granulocytic and monocytic myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) [1][3]. Concurrently, it enhances immune recognition by upregulating tumor-associated antigens, promoting CD8+ T cell infiltration, and altering the expression of immune checkpoint molecules, thereby priming tumors for immune-mediated lysis and synergizing with immunotherapies [2][3].
4. Structure-Activity Relationship (SAR)
Structurally, entinostat (MS-275) belongs to the benzamide class of HDAC inhibitors, distinguishing it from hydroxamic acids (like vorinostat) and cyclic tetrapeptides (like romidepsin) [1][5]. Its synthetic benzamide scaffold confers a high degree of selectivity for class I (and IV) HDACs, avoiding the pan-HDAC inhibition seen with other structural classes. This selectivity is crucial for its specific epigenetic modulation and its favorable pharmacokinetic profile, which includes a long half-life that permits once-weekly oral administration on an empty stomach [1].
The structural features of MS-275 have also inspired the development of novel hybrid compounds designed to maximize anticancer efficacy. For example, SK-7041 is a synthesized hybrid molecule combining structural elements of Trichostatin A (TSA) and MS-275. This hybrid compound has been shown to induce cell apoptosis and G2/M cell cycle arrest, demonstrating potent antitumor activity in breast cancer models [3].
5. Current Limitations
Despite its therapeutic promise, the clinical application of entinostat is hindered by several limitations. Toxicity remains a significant challenge; common adverse events associated with entinostat include fatigue, nausea, vomiting, and hematological toxicities such as neutropenia [1][2]. Furthermore, class I HDAC inhibitors like entinostat have been linked to severe fluid-electrolyte imbalances. Research indicates that class I HDACs are essential for fluid-electrolyte homeostasis in the kidney, and their inhibition by MS-275 can result in polyuria, kidney nitric oxide deficiency, and marked increases in mean arterial pressure [6].
Another limitation is the heterogeneous patient response and the inevitable development of acquired resistance to HDAC inhibitors [2]. The lack of universally validated predictive biomarkers complicates patient selection, although protein lysine hyperacetylation in peripheral blood mononuclear cells (PBMCs) is currently being explored as a potential indicator of entinostat activity [1].
6. Future Perspectives
The future of entinostat and related HDAC inhibitors lies in rational combination strategies. Given its ability to modulate the immune microenvironment and downregulate MDSCs, combining entinostat with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) represents a highly promising frontier for both hematological malignancies and solid tumors [2][3]. Additionally, dual epigenetic therapy—combining entinostat with DNA methyltransferase inhibitors like azacitidine or decitabine—holds potential for robust episensitization, effectively rewriting the tumor's epigenetic code to overcome chemoresistance [4][7].
Future research must also prioritize the identification of robust prognostic and predictive biomarkers (such as PBMC acetylation status or specific gene methylation profiles) to personalize treatment and identify patients most likely to benefit from entinostat [1]. Finally, the development of advanced delivery systems, such as nanoparticle formulations, could help mitigate systemic toxicities and improve the therapeutic index of entinostat [2].
